Wojciech Dworakowski

wojciech Dworakowski joined Flagship Pioneering in 2022 as Vice President, Head of DMPK and Toxicology for Pioneering Medicines.
Wojciech and his team drive the evaluation of drug metabolism, safety, and pharmacokinetic/pharmacodynamic properties of therapeutic agents developed by the portfolio of Pioneering Medicines programs.
Wojciech has a strong background in leading preclinical activities, driving discovery efforts to the IND stage, and supporting clinical evaluation from the preclinical safety, modeling, and human metabolism perspectives.
His expertise includes end-to-end drug development across multiple therapeutic areas, including oncology, CNS/pain, inflammation, and respiratory diseases.
Prior to joining Flagship, he was at Syros Pharmaceuticals, where he provided strategic and tactical input to project teams as they advanced through lead optimization toward IND-enabling studies.
His team also supported the interpretation of safety/efficacy profile in the clinic, and facilitated regulatory interactions required to meet registrational milestones.
Before Syros, Wojciech spent 13 years at Vertex Pharmaceuticals, where he led the preclinical pharmacokinetics and bioanalysis functions.
As a member of multi-disciplinary project teams, he coordinated efforts to hunt for leads and explain mechanisms behind unexpected preclinical findings related to biodistribution, metabolism, efficacy, and safety.
Wojciech received his Ph.D.
in drug metabolism from Warsaw University, Poland, and completed his post-doctoral studies at the University of Pennsylvania.
He holds an M.B.A.
from Boston University and is a graduate of the Wharton Management Program at the University of Pennsylvania.